New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
Portfolio Pulse from
INOVIO announced retrospective data showing that 50% of RRP patients treated with INO-3107 achieved a Complete Response by year 2, up from 28% in the initial trial. This data supports the potential long-term benefits of INO-3107 and will guide future re-dosing strategies.
December 03, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INOVIO's INO-3107 shows improved long-term efficacy in treating RRP, with 50% of patients achieving Complete Response by year 2. This positive data could enhance investor confidence and impact stock prices.
The retrospective data indicates a significant improvement in the efficacy of INO-3107 over time, which is likely to boost investor confidence in INOVIO's product pipeline. The increase in Complete Response rates from 28% to 50% suggests a strong potential for long-term benefits, which could positively impact INOVIO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100